Home Interviews Alligator meets primary endpoint with CD40 agonist in pancreatic cancer

Alligator meets primary endpoint with CD40 agonist in pancreatic cancer

SørenBregenholt, CEO AlligatorBioscience

Alligator meets primary endpoint with CD40 agonist in pancreatic cancer

31 January, 2024

Alligator Bioscience has released positive top-line data from the phase II trial assessing the efficacy of the CD40 agonist mitazalimab in pancreatic cancer. Having met the primary endpoint, the company can now start preparing for phase III. Alligator’s CEO Søren Bregenholt stopped by the BioStock studio in Lund to give us a rundown of the results.

Watch the interview with Alligator Bioscience‘s CEO Søren Bregenholt below.

YouTube video

The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.

Prenumerera på BioStocks nyhetsbrev